TipRanks
CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Want to see CVSI full AI Analyst Report?

CV Sciences (CVSI) Price & Analysis

501 Followers

CVSI Stock Chart & Stats

$0.02
>-$0.01(-5.72%)
At close: 4:00 PM EDT
$0.02
>-$0.01(-5.72%)

Bulls Say, Bears Say

Bulls Say
Stable Gross MarginA gross margin near 49% indicates the product portfolio retains meaningful unit economics despite weaker demand. Maintaining this level gives CV Sciences a foundation to improve operating results if revenue stabilizes, although fixed costs and selling expenses must still be managed effectively.
Product Innovation And DiversificationRecent products already contribute a substantial share of revenue, showing that innovation is translating into commercial activity rather than remaining only a development effort. Expansion into healthy-aging solutions and broader wellness categories may diversify the business beyond its core cannabinoid offering over coming quarters.
Moderate LeverageModerate and improving leverage provides more balance-sheet flexibility than a highly debt-funded model. This can help CV Sciences manage its transition toward newer wellness products, though the relatively thin equity base means continued losses could still reduce that flexibility over time.
Bears Say
Declining RevenueSustained revenue contraction signals weakening demand, distribution, or reorder activity across the company’s product base. A shrinking sales base makes it harder to absorb operating costs, limits investment capacity, and raises the risk that gross-margin strength will not translate into durable earnings improvement.
Persistent Operating LossesRecurring operating and net losses demonstrate that CV Sciences has not converted its roughly 49% gross margin into a profitable business. Continued losses can constrain product investment, weaken equity, and leave results sensitive to modest changes in revenue or operating expenses.
Negative Cash GenerationNegative operating and free cash flow means the company is still not self-funding its operations, even though the burn rate has improved versus earlier years. If profitability does not recover, ongoing cash needs may increase reliance on external capital and limit strategic flexibility.

CV Sciences News

CVSI FAQ

What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
    What is CV Sciences Inc’s market cap?
    CV Sciences Inc’s market cap is $3.05M.
      When is CV Sciences Inc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were CV Sciences Inc’s earnings last quarter?
      Currently, no data Available
      Is CV Sciences Inc overvalued?
      According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does CV Sciences Inc pay dividends?
        CV Sciences Inc does not currently pay dividends.
        What is CV Sciences Inc’s EPS estimate?
        CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does CV Sciences Inc have?
        CV Sciences Inc has 225,829,130 shares outstanding.
          What happened to CV Sciences Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of CV Sciences Inc?
          Currently, no hedge funds are holding shares in CVSI
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            CV Sciences Inc

            CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

            CV Sciences (CVSI) Earnings & Revenues

            CVSI Earnings Call

            Q2 2026
            0:00 / 0:00
            Similar Stocks
            Company
            Price & Change
            Follow
            cbdMD
            ―
            ―
            Cosmos Holdings
            ―
            ―
            IM Cannabis Corp
            ―
            ―
            ―
            ―
            ―
            Incannex Healthcare Limited Sponsored ADR
            ―
            ―

            Ownership Overview

            11.80%<0.01%88.20%
            11.80% Insiders
            <0.01% Other Institutional Investors
            88.20% Public Companies and
            Individual Investors
            Popular Stocks